Effect of Long-term Versus One Time Treatment of Multiple Sclerosis

Doctor Shiva Gopal Vasishta is a medical practitioner in neurology in Voorhees, New Jersey with forty years of practice in this field. Therefore, he holds a great deal of experience, thus providing great insights in his work and practice. He attended the Government Medical College where he graduated in the year 1979 and went on to complete his residency at the Boston City Hospital. He is not only in the neurology practice; he is also a psychiatry specialist.


Doctor Shiva’s practice is currently based in the Eastern Neurodiagnostic Associates and he is affiliated with the Kennedy Health System Cherry Hill Campus. Doctor Gopal Vasishsta and his practice accommodates both English and Spanish, and is certified by The Board of Neurology. He serves different clientele who are covered under various insurance plans such as Medicare, Horizon Blue Cross Blue Shield, and Aetna. This indicates that his practice creates opportunities for people from different walks of life.


Neurologists are engaged in the diagnosis of the peripheral nerves, the spinal cord, muscles, and that of the involuntary nervous system and in the treatment of stroke, epilepsy, and multiple sclerosis. That is the connection of the effect of use of stem cells, which has been found to induce multiple sclerosis with Doctor Gopah Vasishta since his practice involves treatment of this disorder. According to the National Institute of Health, multiple sclerosis is an autoimmune disease that causes the immune system to attack the central nervous system.


After receiving the high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT) treatment, 69 percent of the participants did not experience new brain wounds, relapse of the multiple Sclerosis symptoms or acceleration of disability. This was so despite not taking multiple sclerosis medicines after the treatment. Thus, this clinical trial created an indication that the available medicines for combating multiple sclerosis record lower rates of success.


The one time treatment with the (HDIT/HCT), trial referred as HALT-MS, was found to be more effective compared to the first trial of long-term treatment despite the use of best available drugs especially in people with specific types of multiple sclerosis. This is evidenced by the remission of the HDIT/HCT and the stabilization of the multiple sclerosis of the participants after five years. Further studies are required to fully endorse the benefits of this one treatment, which will affect the practice of neurologists such as Doctor Gopah Vasishta in a positive way especially in those patients that become unresponsive to the existing therapies.